CCR2 and cancer: There is an increasing evidence to the vital anti-proliferative effects of bevacizumab (avastin; AV) (Ferrara et al., 2005) and CCR2 antagonist (CR) (Monti et al., 2003; Wolf et al., 2012; Zhang et al., 2013; Zhang et al., 2010) , and recently their PLGA-based (Hao et al., 2009; Pan et al., 2011) and micelles-based (Roblek et al., 2015) nanoparticulates (NPs) on different cancer cells.